NVST vs ORKA
Envista Holdings vs Oruka Therapeutics, Inc. — AI-powered side-by-side comparison
NVST
Envista Holdings
76
Strong Buy
VS
ORKA
Oruka Therapeutics, Inc.
59
Watch
| Metric | NVST | ORKA |
|---|
| AI Score |
76
|
59
|
| Price |
$28.51
|
$104.56
|
| P/E Ratio |
48.34×
|
-43.80×
|
| ROE |
1.5%
|
-22.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
55.5%
|
0.0%
|
| Debt / Equity |
0.52×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
59.3
|
74.0
|
| Beta |
0.861
|
-0.389
|
| Expected Upside |
+1.4%
|
—
|
AI Committee View
Current Innellis committee reasoning for NVST versus ORKA.
NVST leads by 17 points.
NVST scores 76/100 (Strong Buy) versus ORKA at 59/100 (Watch).
NVST Committee View
100% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- Weekly trend is bearish while daily is bullish — against the higher-timeframe trend.
- Risk/reward is unfavorable: 14.2% downside vs 1.4% upside.
ORKA Committee View
60% agreement
5 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -26.0% -- cheap may mean cheap for a reason — Value
- RSI at 74 is in overbought territory — Technical
- Weekly RSI at 86 -- overbought on the larger timeframe too — Technical